… treatment with molnupiravir (Table 3). A post hoc analysis examined outcomes among
immunocompromised participants… , fewer molnupiravir-treated immunocompromised patients were …

… from nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection. …
Such drugs are also needed for the treatment of immunodeficient patients who do not mount a (…

… from EHRs from participating healthcare organizations, … treatment with other approved
medications for COVID-19 such as monoclonal antibody, convalescent plasma, or molnupiravir for …

… ) of this trial, molnupiravir treatment resulted in a 3 percentage … in detail the selection criteria
of participants and how to assess … Should immunocompromised patients always have priority …

… in an immunosuppressed patient treated with a combination of nirmatrelvir/ritonavir (N/r) plus
molnupiravir for … All procedures performed in studies involving human participants were in …

… second-line therapy (molnupiravir) reduces the prevalence of … , such as those who are
immunocompromised (14). Two … /ritonavir treatment among immunocompromised subjects ¶¶ and …

… COVID-19 management, not as a competitor to vaccination. … for oral antivirals development
to treat COVID-19, highlight … (nirmatrelvir/ritonavir and molnupiravir), and present the potential …

… The data shows that within a 28-day window from prescription, 6.2% of all the participants
in … study suggest that antiviral treatment with Paxlovid, molnupiravir and sotrovimab may be …

… participants. The number of seropositive individuals who achieved the primary endpoint was
low in the molnupiravir study (n = 5/136 in molnupiravir … treatment of immunocompromised …

… /ritonavir and molnupiravir before hospitalisation on … COVID-19, the study participants were
divided into three groups, … rates in the setting of outpatient treatment and mild disease [3,4]. …